Das kleinzellige Bronchialkarzinom

Tumorregister München (TRM) (2001) www.tumorregister-muenchen.de Statistik Austria: Österreichisches Krebsregister (2006) www.statistik.at Govindan R, Page N, Morgensztern D, Read W, Tierney R, Vlahiotis A, et al (2006) Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database. J Clin Oncol 24 (28): 4539–4544 Tiroler Arbeitskreis für Onkologie (TAKO) (2006) TAKO Guidelines www.tako.or.at Barbone F, Bovenzi M, Cavallieri F, Stanta G (1997) Cigarette smoking and histologic type of lung cancer in men. Chest 112 (6): 1474–1479 de Andrade M, Ebbert JO, Wampfler JA, Miller DL, Marks RS, Croghan GA, et al (2004) Environmental tobacco smoke exposure in women with lung cancer. Lung Cancer 43 (2): 127–134 Wittekind CH, Wagner G für die UICC (1997) TNM Klassifikation maligner Tumoren. Springer, Berlin Heidelberg New York Deutsche Krebsgesellschaft (2004) Therapie des kleinzelligen Lungenkarzinom. Kurzgefaßte interdisziplinäre Leitlinien. Diagnostik und Therapie maligner Erkrankungen. W. Zuckschwerdt Verlag, München Bern Wien New York, www.krebsgesellschaft.de/download/c1_kleinzlungenkarzinom.pdf Wolf M HK (1995) Kleinzellige Bronchialkarzinome. In: Seeber S, Schütte J (Hrsg) Therapiekonzepte Onkologie 2. Springer, Berlin Heidelberg New York, pp 420–445 Wittekind C, Compton CC, Greene FL, Sobin LH (2002) TNM residual tumor classification revisited. Cancer 94 (9): 2511–2516 Schmoll HJ, Höffken K, Possinger K (2006) Kompendium Internistischer Onkologie. Standards in Diagnostik und Therapie, pp 3591 Yip D, Harper PG (2000) Predictive and prognostic factors in small cell lung cancer: current status. Lung Cancer 28 (3): 173–185 Agra Y, Pelayo M, Sacristan M, Sacristan A, Serra C, Bonfill X (2003) Chemotherapy versus best supportive care for extensive small cell lung cancer. Cochrane Database Syst Rev (4): CD001990 Zelen M (1973) Keynote address on biostatistics and data retrieval. Chemotherapy versus best supportive care for extensive small cell lung cancer. Cancer Chemother Rep 34 (2): 31–42 Medical Research Council Lung Cancer Working Party (1979) Radiotherapy alone or with chemotherapy in the treatment of small-cell carcinoma of the lung. Br J Cancer 40 (1): 1–10 Grant SC, Gralla RJ, Kris MG, Orazem J, Kitsis EA (1992) Single-agent chemotherapy trials in small-cell lung cancer, 1970 to 1990: the case for studies in previously treated patients. J Clin Oncol 10 (3): 484–498 Argiris A, Murren JR (2001) Advances in chemotherapy for small cell lung cancer: single-agent activity of newer agents. Cancer J 7 (3): 228–235 Livingston RB (1978) Treatment of small cell carcinoma: evolution and future directions. Semin Oncol 5 (3): 299–308 Lassen UN, Hirsch FR, Osterlind K, Bergman B, Dombernowsky P (1998) Outcome of combination chemotherapy in extensive stage small-cell lung cancer: any treatment related progress? Lung Cancer 20 (3): 151–160 Warde P, Payne D (1992) Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 10 (6): 890–895 Pujol JL, Quantin X, Choma D, Carestia L, Jacot W (2000) Management of small-cell bronchial cancer. Rev Pneumol Clin [Suppl] 2: 4–13 Sundstrom S, Bremnes RM, Kaasa S, Aasebo U, Hatlevoll R, Dahle R, et al (2002) Cisplatin and etoposide regimen is superior to cyclophosphamide, epirubicin, and vincristine regimen in small-cell lung cancer: results from a randomized phase III trial with 5 years' follow-up. J Clin Oncol 20 (24): 4665–4672 Skarlos DV, Samantas E, Kosmidis P, Fountzilas G, Angelidou M, Palamidas P, et al (1994) Randomized comparison of etoposide-cisplatin vs. etoposide-carboplatin and irradiation in small-cell lung cancer. A Hellenic Co-operative Oncology Group study. Ann Oncol 5 (7): 601–607 Turrisi AT, III, Kim K, Blum R, Sause WT, Livingston RB, Komaki R, et al (1999) Twice-daily compared with once-daily thoracic radiotherapy in limited small-cell lung cancer treated concurrently with cisplatin and etoposide. N Engl J Med 340 (4): 265–271 Warde P, Payne D (1992) Does thoracic irradiation improve survival and local control in limited-stage small-cell carcinoma of the lung? A meta-analysis. J Clin Oncol 10 (6): 890–895 De Ruysscher D, Pijls-Johannesma M, Bentzen SM, Minken A, Wanders R, et al (2006) Time between the first day of chemotherapy and the last day of chest radiation is the most important predictor of survival in limited-disease small-cell lung cancer. J Clin Oncol 24 (7): 1057–1063 Murray N, Coy P, Pater JL, Hodson I, Arnold A, Zee BC, et al (1993) Importance of timing for thoracic irradiation in the combined modality treatment of limited-stage small-cell lung cancer. The National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 11 (2): 336–344 Fried DB, Morris DE, Poole C, Rosenman JG, Halle JS, Detterbeck FC, et al (2004) Systematic review evaluating the timing of thoracic radiation therapy in combined modality therapy for limited-stage small-cell lung cancer. J Clin Oncol 22 (23): 4837–4845 Thatcher N, Girling DJ, Hopwood P, Sambrook RJ, Qian W, Stephens RJ (2000) Improving survival without reducing quality of life in small-cell lung cancer patients by increasing the dose-intensity of chemotherapy with granulocyte colony-stimulating factor support: results of a British Medical Research Council Multicenter Randomized Trial. Medical Research Council Lung Cancer Working Party. J Clin Oncol 18 (2): 395–404 Turrisi AT, III, Glover DJ, Mason BA (1988) A preliminary report: concurrent twice-daily radiotherapy plus platinum-etoposide chemotherapy for limited small cell lung cancer. Int J Radiat Oncol Biol Phys 15 (1): 183–187 Schild SE, Bonner JA, Shanahan TG, Brooks BJ, Marks RS, Geyer SM, et al (2004) Long-term results of a phase III trial comparing once-daily radiotherapy with twice-daily radiotherapy in limited-stage small-cell lung cancer. Int J Radiat Oncol Biol Phys 59 (4): 943–951 Turrisi AT, III, Glover DJ (1990) Thoracic radiotherapy variables: influence on local control in small cell lung cancer limited disease. Int J Radiat Oncol Biol Phys 19 (6): 1473–1479 Hansen HH, Dombernowsky P, Hirsch FR, Hansen M, Rygard J (1980) Prophylactic irradiation in bronchogenic small cell anaplastic carcinoma. A comparative trial of localized versus extensive radiotherapy including prophylactic brain irradiation in patients receiving combination chemotherapy. Cancer 46 (2): 279–284 Arriagada R LCTB (1995) Prophylactic cranial irradiation (PCI) for patients with small cell lung cancer (SCLC) in complete remission. J Natl Cancer Inst 87: 183 Auperin A, Arriagada R, Pignon JP, Le Pechoux C, Gregor A, Stephens RJ, et al (1999) Prophylactic cranial irradiation for patients with small-cell lung cancer in complete remission. Prophylactic Cranial Irradiation Overview Collaborative Group. N Engl J Med 341 (7): 476–484 Kotalik J, Yu E, Markman BR, Evans WK (2001) Practice guideline on prophylactic cranial irradiation in small-cell lung cancer. Int J Radiat Oncol Biol Phys 50 (2): 309–316 Veronesi G, Scanagatta P, Leo F, De Pas T, Pelosi G, Catalano G, et al (2007) Adjuvant surgery after carboplatin and VP16 in resectable small cell lung cancer. J Thorac Oncol 2 (2): 131–134 de Antonio DG, Alfageme F, Gamez P, Cordoba M, Varela A (2006) Results of surgery in small cell carcinoma of the lung. Lung Cancer 52 (3): 299–304 Lad T, Piantadosi S, Thomas P, Payne D, Ruckdeschel J, Giaccone G (1994) A prospective randomized trial to determine the benefit of surgical resection of residual disease following response of small cell lung cancer to combination chemotherapy. Chest 106 [6 Suppl]: 320S–323S Lucchi M, Mussi A, Chella A, Janni A, Ribechini A, Menconi GF, et al (1997) Surgery in the management of small cell lung cancer. Eur J Cardiothorac Surg 12 (5): 689–693 Karrer K, Ulsperger E (1995) Surgery for cure followed by chemotherapy in small cell carcinoma of the lung. For the ISC-Lung Cancer Study Group. Acta Oncol 34 (7): 899–906 Shepherd FA, Ginsberg RJ, Feld R, Evans WK, Johansen E (1991) Surgical treatment for limited small-cell lung cancer. The University of Toronto Lung Oncology Group experience. J Thorac Cardiovasc Surg 101 (3): 385–393 Fujimori K, Yokoyama A, Kurita Y, Terashima M (1997) A pilot phase 2 study of surgical treatment after induction chemotherapy for resectable stage I to IIIA small cell lung cancer. Chest 111 (4): 1089–1093 Kies MS, Mira JG, Crowley JJ, Chen TT, Pazdur R, Grozea PN, et al (1987) Multimodal therapy for limited small-cell lung cancer: a randomized study of induction combination chemotherapy with or without thoracic radiation in complete responders; and with wide-field versus reduced-field radiation in partial responders: a Southwest Oncology Group Study. J Clin Oncol 5 (4): 592–600 Badzio A, Kurowski K, Karnicka-Mlodkowska H, Jassem J (2004) A retrospective comparative study of surgery followed by chemotherapy vs. non-surgical management in limited-disease small cell lung cancer. Eur J Cardiothorac Surg 26 (1): 183–188 Baumann P, Nyman J, Lax I, Friesland S, Hoyer M, Rehn ES, et al (2006) Factors important for efficacy of stereotactic body radiotherapy of medically inoperable stage I lung cancer. A retrospective analysis of patients treated in the Nordic countries. Acta Oncol 45 (7): 787–795 Zimmermann FB, Geinitz H, Schill S, Thamm R, Nieder C, Schratzenstaller U, et al (2006) Stereotactic hypofractionated radiotherapy in stage I (T1-2 N0 M0) non-small-cell lung cancer (NSCLC). Acta Oncol 45 (7): 796–801 Slotman B, Faivre-Finn C, Kramer G, Rankin E, Snee M, et al (2007) A randomized trial of prophylactic cranial irradiation (PCI) versus no PCI in extensive disease small cell lung cancer after a response to chemotherapy J Clin Oncol 24 (18S): Abstract-No 4 Ardizzoni A, Hansen H, Dombernowsky P, Gamucci T, Kaplan S, Postmus P, et al (1997) Topotecan, a new active drug in the second-line treatment of small-cell lung cancer: a phase II study in patients with refractory and sensitive disease. The European Organization for Research and Treatment of Cancer Early Clinical Studies Group and New Drug Development Office, and the Lung Cancer Cooperative Group. J Clin Oncol 15 (5): 2090–2096 Murphy PB, Hainsworth JD, Spigel DR, Gray JR, Liggett WH, Shipley DL, Switzer A, et al (2006) Topotecan- Single agent activity in a weekly intravenous (IV) schedule for first-line therapy in poor prognosis extensive stage small cell lung cancer (SCLC): A Minnie Pearl Cancer Research Network phase II trial. J Clin Oncol 24 (18S): Abstract-No 17000 Noda K, Nishiwaki Y, Kawahara M, Negoro S, Sugiura T, Yokoyama A, et al (2002) Irinotecan plus cisplatin compared with etoposide plus cisplatin for extensive small-cell lung cancer. N Engl J Med 346 (2): 85–91 Hanna N, Bunn PA Jr, Langer C, Einhorn L, Guthrie T Jr, Beck T, et al (2006) Randomized phase III trial comparing irinotecan/cisplatin with etoposide/cisplatin in patients with previously untreated extensive-stage disease small-cell lung cancer. J Clin Oncol 24 (13): 2038–2043 Lara P Jr (2007) Cisplatin (Cis)/etoposide (VP16) compared to cis/irinotecan (CPT11) in extensive-stage small cell lung cancer (E-SCLC): Pharmacogenomic (PG) and comparative toxicity analysis of JCOG 9511 and SWOG 0124. J Clin Oncol 25 (18S): Abstract No 7524 Greco FA (2003) Topotecan as first-line therapy for small cell lung cancer. Lung Cancer 41 [Suppl 4]: S9–S16 Hermes A (2007) A randomized phase III trial of irinotecan plus carboplatin versus etoposide plus carboplatin in patients with small cell lung cancer, extensive disease (SCLC-ED): IRIS-Study. J Clin Oncol 25 (18S): Abstract No 7523 Perez-Soler R, Glisson BS, Lee JS, Fossella FV, Murphy WK, Shin DM, et al (1996) Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan. J Clin Oncol 14 (10): 2785–2790 von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, et al (1999) Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17 (2): 658–667 Sundstrom S, Bremnes RM, Kaasa S, Aasebo U, Aamdal S (2005) Second-line chemotherapy in recurrent small cell lung cancer. Results from a crossover schedule after primary treatment with cisplatin and etoposide (EP-regimen) or cyclophosphamide, epirubicin, and vincristin (CEV-regimen). Lung Cancer 48 (2): 251–261 Shepherd FA, Evans WK, MacCormick R, Feld R, Yau JC (1987) Cyclophosphamide, doxorubicin, and vincristine in etoposide- and cisplatin-resistant small cell lung cancer. Cancer Treat Rep 71 (10): 941–944 Evans WK, Osoba D, Feld R, Shepherd FA, Bazos MJ, DeBoer G (1985) Etoposide (VP-16) and cisplatin: an effective treatment for relapse in small-cell lung cancer. J Clin Oncol 3 (1): 65–71 Ettinger DS (2001) New drugs for chemotherapy-naïve patients with extensive-disease small cell lung cancer. Semin Oncol 28 [2 Suppl 4]: 27–29 Kelly K (2000) New chemotherapy agents for small cell lung cancer. Chest 117 [4 Suppl 1]: 156S–162S von Pawel J, Schiller JH, Shepherd FA, Fields SZ, Kleisbauer JP, Chrysson NG, et al (1999) Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer. J Clin Oncol 17 (2): 658–667 O'Brien ME, Ciuleanu TE, Tsekov H, Shparyk Y, Cucevia B, Juhasz G, et al (2006) Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 24 (34): 5441–5447 O'Brien ME, Ciuleanu TE, Tsekov H, Shparyk Y, Cucevia B, Juhasz G, et al (2006) Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 24 (34): 5441–5447 Ardizzoni A (2004) Topotecan in the treatment of recurrent small cell lung cancer: an update. Oncologist 9 [Suppl 6]: 4–13 Ardizzoni A, Manegold C, Debruyne C, Gaafar R, Buchholz E, Smit EF, et al (2003) European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer. Clin Cancer Res 9 (1): 143–150 von Pawel J, Gatzemeier U, Pujol JL, Moreau L, Bildat S, Ranson M, et al (2001) Phase ii comparator study of oral versus intravenous topotecan in patients with chemosensitive small-cell lung cancer. J Clin Oncol 19 (6): 1743–1749 Raju RN (2007) Pemetrexed (P) in relapsed small cell lung cancer (SCLC): Preliminary results of a phase II trial. J Clin Oncol 25 (18S) Abstract No 7716 de Jong WK, ten Hacken NH, Groen HJ (2006) Third-line chemotherapy for small cell lung cancer. Lung Cancer 52 (3): 339–342 Schmoll HJ, Höffken K, Possinger K (2006) Kompendium Internistischer Onkologie Standards in Diagnostik und Therapie. Springer, Wien New Work, pp 3603 Wedding U, Honecker F, Bokemeyer C, Pientka L, Hoffken K (2007) Tolerance to chemotherapy in elderly patients with cancer. Cancer Control 14 (1): 44–56 Sekine I, Yamamoto N, Kunitoh H, Ohe Y, Tamura T, Kodama T, et al (2004) Treatment of small cell lung cancer in the elderly based on a critical literature review of clinical trials. Cancer Treat Rev 30 (4): 359–368 Matsui K, Masuda N, Yana T, Takada Y, Kobayashi M, Nitta T, et al (2001) Carboplatin calculated with Chatelut' s formula plus etoposide for elderly patients with small-cell lung cancer. Intern Med 40 (7): 603–606 Evans WK, Radwi A, Tomiak E, Logan DM, Martins H, Stewart DJ, et al (1995) Oral etoposide and carboplatin. Effective therapy for elderly patients with small cell lung cancer. Am J Clin Oncol 18 (2): 149–155 Jeremic B, Shibamoto Y, Acimovic L, Milisavljevic S (1998) Carboplatin, etoposide, and accelerated hyperfractionated radiotherapy for elderly patients with limited small cell lung carcinoma: a phase II study. Cancer 82 (5): 836–841 Murray N, Grafton C, Shah A, Gelmon K, Kostashuk E, Brown E, et al (1998) Abbreviated treatment for elderly, infirm, or noncompliant patients with limited-stage small-cell lung cancer. J Clin Oncol 16 (10): 3323–3328 Garst J, Buller R, Lane S, Crawford J (2005) Topotecan in the treatment of elderly patients with relapsed small-cell lung cancer. Clin Lung Cancer 7 (3): 190–196 O'Brien ME, Ciuleanu TE, Tsekov H, Shparyk Y, Cucevia B, Juhasz G, et al (2006) Phase III trial comparing supportive care alone with supportive care with oral topotecan in patients with relapsed small-cell lung cancer. J Clin Oncol 24 (34): 5441–5447 Cooper S, Spiro SG (2006) Small cell lung cancer: treatment review. Respirology 11 (3): 241–248 Johnson DH, Carbone DP (1999) Increased dose-intensity in small-cell lung cancer: a failed strategy? J Clin Oncol 17 (8): 2297–2299 Ziske C, Gorschluter M, Mey U, Offergeld R, Glasmacher A, Schmidt-Wolf IG (2002) Sequential high-dose chemotherapy with autologous stem cell support in patients with limited-stage small cell lung cancer. Anticancer Res 22 (6B): 3723–3726 Giaccone G, Dalesio O, McVie GJ, Kirkpatrick A, Postmus PE, Burghouts JT, et al (1993) Maintenance chemotherapy in small-cell lung cancer: long-term results of a randomized trial. European Organization for Research and Treatment of Cancer Lung Cancer Cooperative Group. J Clin Oncol 11 (7): 1230–1240 Spiro SG, Souhami RL, Geddes DM, Ash CM, Quinn H, Harper PG, et al (1989) Duration of chemotherapy in small cell lung cancer: a Cancer Research Campaign trial. Br J Cancer 59 (4): 578–583 Steward WP, von Pawel J, Gatzemeier U, Woll P, Thatcher N, Koschel G, et al (1998) Effects of granulocyte-macrophage colony-stimulating factor and dose intensification of V-ICE chemotherapy in small-cell lung cancer: a prospective randomized study of 300 patients. J Clin Oncol 16 (2): 642–650 Roth BJ, Johnson DH, Einhorn LH, Schacter LP, Cherng NC, Cohen HJ, et al (1992) Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alternation of these two regimens in extensive small-cell lung cancer: a phase III trial of the Southeastern Cancer Study Group. J Clin Oncol 10 (2): 282–291 Rowell NP, Gleeson FV (2001) Steroids, radiotherapy, chemotherapy and stents for superior vena caval obstruction in carcinoma of the bronchus. Cochrane Database Syst Rev (4): CD001316 Armstrong BA, Perez CA, Simpson JR, Hederman MA (1987) Role of irradiation in the management of superior vena cava syndrome. Int J Radiat Oncol Biol Phys 13 (4): 531–539 Tai P, Yu E, Jones K, Sadikov E, Mahmood S, Tonita J (2006) Syndrome of inappropriate antidiuretic hormone secretion (SIADH) in patients with limited stage small cell lung cancer. Lung Cancer 53 (2): 211–215 Decaux G, Waterlot Y, Genette F, Mockel J (1981) Treatment of the syndrome of inappropriate secretion of antidiuretic hormone with furosemide. N Engl J Med 304 (6): 329–330 Poe CM, Taylor LM (1989) Syndrome of inappropriate antidiuretic hormone: assessment and nursing implications. Oncol Nurs Forum 16 (3): 373–381 Verbalis J (2007) Vasporessin V1A and V2 antagonoist conivaptan increases serum sodium concentration and effective water clearance in hyponatremia. Bisaha JSNN, editor. J Am Soc Nephrol [15]: 346A Mason WP, Graus F, Lang B, Honnorat J, Delattre JY, Valldeoriola F, et al (1997) Small-cell lung cancer, paraneoplastic cerebellar degeneration and the Lambert-Eaton myasthenic syndrome. Brain 120 (Pt 8): 1279–1300 Fraisse T, Labauge P, Camu W, Arlaud P, de Wazieres B (2007) Myathenia gravis in the elderly: diagnosis, comorbidity and course: 45 cases. Presse Med 36 (1 Pt 1): 9–14 Gaspar LE, Scott C, Murray K, Curran W (2000) Validation of the RTOG recursive partitioning analysis (RPA) classification for brain metastases. Int J Radiat Oncol Biol Phys 47 (4): 1001–1006 Bezjak A, Adam J, Barton R, Panzarella T, Laperriere N, Wong CS, et al (2002) Symptom response after palliative radiotherapy for patients with brain metastases. Eur J Cancer 38 (4): 487–496 Sheehan J, Kondziolka D, Flickinger J, Lunsford LD (2005) Radiosurgery for patients with recurrent small cell lung carcinoma metastatic to the brain: outcomes and prognostic factors. J Neurosurg 102 [Suppl]: 247–254 Pan HC, Sheehan J, Stroila M, Steiner M, Steiner L (2005) Gamma knife surgery for brain metastases from lung cancer. J Neurosurg 102 [Suppl]: 128–133 Nagata Y, Takayama K, Matsuo Y, Norihisa Y, Mizowaki T, Sakamoto T, et al (2005) Clinical outcomes of a phase I/II study of 48 Gy of stereotactic body radiotherapy in 4 fractions for primary lung cancer using a stereotactic body frame. Int J Radiat Oncol Biol Phys 63 (5): 1427–1431 Antonadou D, Paraskevaidis M, Sarris G, Coliarakis N, Economou I, Karageorgis P, et al (2002) Phase II randomized trial of temozolomide and concurrent radiotherapy in patients with brain metastases. J Clin Oncol 20 (17): 3644–3650 Lee RB (2000) Surgical palliation of airway obstruction resulting from lung cancer. Semin Surg Oncol 18 (2): 173–182 McQuay HJ, Collins SL, Carroll D, Moore RA (2000) Radiotherapy for the palliation of painful bone metastases. Cochrane Database Syst Rev (2): CD001793 Dutau H, Toutblanc B, Lamb C, Seijo L (2004) Use of the Dumon Y-stent in the management of malignant disease involving the carina: a retrospective review of 86 patients. Chest 126 (3): 951–958 Harms W, Schraube P, Becker H, Latz D, Herth F, Fritz P, et al (2000) Effect and toxicity of endoluminal high-dose-rate (HDR) brachytherapy in centrally located tumors of the upper respiratory tract. Strahlenther Onkol 176 (2): 60–66 Herth FJF (2005) Interventionelle Therapie beim endobronchialem Tumorbefall. Freitag L, Onkologe, pp 759–767 DeVita VT (2005) Specifics of lung cancer management. In: Hellmann SRS (ed) Pleurodesis of malignant pleural effusions, pp 625–626 Gotoh T, Nakamura T, Hiramori N, Fujii T, Fujita Y, Kida T, et al (1991) Intrapleural administration of pirarubicin in the treatment of malignant pleural effusion. Gan To Kagaku Ryoho 18 (12): 2121–2127 Blackhall FH, Shepherd FA (2007) Small cell lung cancer and targeted therapies. Curr Opin Oncol 19 (2): 103–108 Sandler A (2007) A phase II study of cisplatin (P) plus etoposide (E) plus bevacizumab (B) for previously un-treated extensive stage small cell lung cancer (SCLC) (E3501): A trial of the Eastern Cooperative Oncology Group. J Clin Oncol 25 (18S): Abstract No 7564 Pujol JL, Breton JL, Gervais R, Tanguy ML, Quoix E, David P, et al (2007) Phase III double-blind, placebo-controlled study of thalidomide in extensive-disease small-cell lung cancer after response to chemotherapy: an intergroup study FNCLCC cleo04 IFCT 00-01. J Clin Oncol 25 (25): 3945–3951 Spigel DR, Hainsworth JD, Yardley LA, Burris HA, Farley C (2007 Phase II trial of irinotecan, carboplatin, and bevacizumab in patients with extensive-stage small cell lung cancer. J Clin Oncol 25 (18S): Abstract No 18130 Zubkus JD, Spigel DR, Greco FA, Yardley DA, Burris HA, et al (2007) Phase II trial of irinotecan, carboplatin, and bevacizumab in patients with limited-stage small cell lung cancer. J Clin Oncol 25 (18S): Abstract No 18133 Kulpa J, Wojcik E, Reinfuss M, Kolodziejski L (2002) Carcinoembryonic antigen, squamous cell carcinoma antigen, CYFRA 21-1, and neuron-specific enolase in squamous cell lung cancer patients. Clin Chem 48 (11): 1931–1937 Fukuoka M, Furuse K, Saijo N, Nishiwaki Y, Ikegami H, Tamura T, et al (1991) Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small-cell lung cancer. J Natl Cancer Inst 83 (12): 855–861 Eckardt JR, von Pawel J, Papai Z, Tomova A, Tzekova V, Crofts TE, et al (2006) Open-label, multicenter, randomized, phase III study comparing oral topotecan/cisplatin versus etoposide/cisplatin as treatment for chemotherapy- naive patients with extensive-disease small-cell lung cancer. J Clin Oncol 24 (13): 2044–2051 Artel-Cortes A, Gomez-Codina J, Gonzalez-Larriba JL, Barneto I, Carrato A, Isla D, et al (2004) Prospective randomized phase III trial of etoposide/cisplatin versus high-dose epirubicin/cisplatin in small-cell lung cancer. Clin Lung Cancer 6 (3): 175–183 Niell HB, Herndon JE, Miller AA, Watson DM, Sandler AB, Kelly K, et al (2005) Randomized phase III intergroup trial of etoposide and cisplatin with or without paclitaxel and granulocyte colony-stimulating factor in patients with extensive-stage small-cell lung cancer: Cancer and Leukemia Group B Trial 9732. J Clin Oncol 23 (16): 3752–3759 Mavroudis D, Papadakis E, Veslemes M, Tsiafaki X, Stavrakakis J, Kouroussis C, et al (2001) A multicenter randomized clinical trial comparing paclitaxel-cisplatin-etoposide versus cisplatin-etoposide as first-line treatment in patients with small-cell lung cancer. Ann Oncol 12 (4): 463–470 Reck M, von Pawel J, Macha HN, Kaukel E, Deppermann KM, Bonnet R, et al (2003) Randomized phase III trial of paclitaxel, etoposide, and carboplatin versus carboplatin, etoposide, and vincristine in patients with small-cell lung cancer. J Natl Cancer Inst 95 (15): 1118–1127 Loehrer PJ, Sr., Ansari R, Gonin R, Monaco F, Fisher W, Sandler A, et al (1995) Cisplatin plus etoposide with and without ifosfamide in extensive small-cell lung cancer: a Hoosier Oncology Group study. J Clin Oncol 13 (10): 2594–2599 Miyamoto H, Nakabayashi T, Isobe H, Akita H, Kawakami Y, Arimoto T, et al (1992) A phase III comparison of etoposide/cisplatin with or without added ifosfamide in small-cell lung cancer. Oncology 49 (6): 431–435